13. 多発性硬化症／視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details
臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04106830 (ClinicalTrials.gov) | January 1, 2019 | 25/9/2019 | Clinical and Imaging Patterns of Neuroinflammation Diseases in China (CLUE) | Prospective Cohort Study of Clinical and Imaging Patterns of Neuroinflammation Diseases (CLUE) | NMO Spectrum Disorder;MRI;Multiple Sclerosis | Drug: Intravenous steroid | Beijing Tiantan Hospital | NULL | Recruiting | 16 Years | 80 Years | All | 1000 | China | |
| 2 | NCT01411514 (ClinicalTrials.gov) | August 2011 | 26/5/2011 | Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis | Phase IV Study of Oral Prednisone Taper vs. Placebo Following Intravenous Steroids for the Treatment of Acute Relapses in Multiple Sclerosis Within the Ticino Cohort | Multiple Sclerosis | Drug: Prednisone;Drug: Placebo | Claudio Gobbi | Ente Ospedaliero Cantonale, Ticino, Switzerland | Terminated | 18 Years | 80 Years | Both | 27 | Phase 4 | Switzerland |